Current Ocrelizumab Trials that are recruiting subjects

Study 1A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis (NCT01194570)

Eligibility:

Inclusion Criteria:
Exclusion Criteria:


Study 2A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis (NCT01412333)

Eligibility:

Inclusion Criteria:
Exclusion Criteria:

Study 3A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis (NCT01247324)

Eligibility:

Inclusion Criteria:
Exclusion Criteria:


"Please note that two registration trials are being done for RRMS and one in PPMS. Two trials are needed for RRMS to make sure that if the results of one trial are positive they are not spurious, i.e. a false positive due to chance. Two trials also allows the sponsor to acquire additional safety data; regulators are particularly keen to have safety data on a large number of subjects."


"Only one PPMS trial is probably needed as this is a relatively uncommon form of MS without a licensed treatment at present; in other words there is an unmet need for a therapy in PPMS. The EMA and FDA are likely to treat PPMS in a similar way to an orphan disease; in other words they will only require one registration trial to license a therapy in PPMS."

CoI: We are a participating site for both the primary progressive and relapsing-remitting trials and I am a member of the steering committee for the PPMS trial.